QT
JNCE

Quantamental Technologies’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Quantamental Technologies’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,955
Closed -$7K – 1482
2019
Q3 		$7K Sell
1,955
-200
-9% -$801 ﹤0.01% 1363
2019
Q2 		$11K Buy
+2,155
New +$11.4K ﹤0.01% 1241

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Quantamental Technologies's JNCE Position: Q4 2019 in Review

Quantamental Technologies sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2019, closing a stake of 1,955 shares — an estimated $7K sold.

Quantamental Technologies first reported a position in JNCE in Q2 2019 and held it in 2 quarters. The position peaked at $11K in Q2 2019. 100 funds tracked by Wall St. Rank hold JNCE as of Q4 2019.

  • Quantamental Technologies reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Quantamental Technologies sold 1,955 Jounce Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $7K.
  • Quantamental Technologies first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2019 and held it in 2 quarters.
  • Quantamental Technologies's Jounce Therapeutics, Inc. Common Stock position peaked at $11K in Q2 2019.
  • 100 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Quantamental Technologies's 13F filing for Q4 2019, filed 14 Feb 2020.